Cleerly stock
Private-market facts for current and former Cleerly employees researching their stock.
Overview
Cleerly uses AI to analyze cardiac CT scans and quantify atherosclerosis (plaque buildup in heart arteries), enabling cardiologists to detect heart disease earlier and more precisely than traditional methods.
Cleerly outlook
For employees evaluating Cleerly equity, a 1x base multiple suggests the stock may be close to fairly valued at current prices.
These estimates reflect modeled return scenarios, not guaranteed outcomes. Actual results depend on company performance, market conditions, share class, and timing.
Selling Cleerly shares
Why shareholders consider selling
Shareholders in Cleerly may explore liquidity for a number of reasons — diversifying a concentrated position, funding a personal financial goal, or simply reducing exposure to a single private holding. As a private company, Cleerly does not trade on a public exchange, meaning employees and early shareholders cannot simply sell through a brokerage. Extended private timelines can leave shareholders waiting years for an exit event, which is why some choose to explore secondary-market options.
Can you sell Cleerly stock?
Whether a shareholder can sell typically depends on what they hold and how it was acquired. Vested and exercised shares are generally more straightforward than unexercised options or unvested RSUs. Most private companies, including those in the Healthcare & Biotech sector, impose transfer restrictions such as rights of first refusal or board approval requirements. The specific terms governing Cleerly shares would be outlined in the holder's equity agreement or the company's governing documents.
What affects the value of Cleerly shares?
The price a buyer is willing to pay for private shares is shaped by several factors: overall demand for the stock, the company's financial performance, broader Healthcare & Biotech market conditions, and any recent private-market transaction activity. Data points such as the company's Series C round can help frame expectations, though they do not guarantee a transaction price.
What should holders check before selling
- The type of security held (common shares, preferred, options, RSUs)
- Whether the equity is fully vested and, for options, whether it has been exercised
- Any transfer restrictions, lock-up provisions, or company approval requirements
- Estimated net proceeds after applicable taxes and transaction fees
- Whether partial liquidity — selling a portion rather than the full position — may be a better fit
Tools for Cleerly shareholders
Exploring equity in Cleerly often raises questions about taxes, exercise timing, valuation, and exit outcomes. These tools can help you model different decisions using your own assumptions.
Latest funding round
Cleerly most recently raised a Series C round . Total funding raised to date is approximately $323M.
Lead investors in this round include Insight Partners.
Founders & company background
Cleerly was founded in 2017 by James Min and is headquartered in New York, NY.
Investors
Industry
Similar private companies
Latest Cleerly news
Frequently asked questions
- Is Cleerly still a private company?
- Yes, Cleerly is currently a private company.
- What is Cleerly's latest funding round?
- Cleerly's most recent known round is Series C.
- What is Cleerly's valuation?
- Cleerly's valuation has not been publicly disclosed.
- Who are the investors in Cleerly?
- Notable investors include Insight Partners.
- Can I sell my Cleerly stock?
- Private company shares can sometimes be sold on secondary markets. Speaking with a specialist who understands Cleerly stock can help you evaluate your options.
Related pages
Last verified: 2026-04-13 · Cleerly data compiled from funding disclosures, investor announcements, corporate filings, and public records.
Information on this page is compiled from publicly available sources and may be outdated or incomplete. This is not investment advice. Consult a qualified advisor before making financial decisions.